Last updated: February 27, 2026
What is the Drug with NDC 70677-1112?
NDC 70677-1112 corresponds to Efgartigimod alfa-fpes, a monoclonal antibody marketed under the name Vyvgart. It is approved for treating generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody-positive.
Current Market Position
- Indication: Approved by the FDA in 2021 for gMG.
- Manufacturer: argenx SE.
- Pricing: The wholesale acquisition cost (WAC) for Vyvgart initially stood at approximately $8,000 per 10 mg vial, with treatment regimens typically involving multiple vials per infusion.
Market Dynamics
Competitor Landscape
- Existing therapies: Eculizumab (Soliris), approved for gMG, priced at approximately $600,000 annually.
- Emerging options: Zilucoplan (regulatory filings), which potentially offers similar efficacy at lower costs.
- Market size: Estimated prevalence of gMG in the U.S. at 60,000–75,000 patients, with roughly 30–50% being AChR antibody-positive.
Market Penetration
- Vyvgart's segment capture is limited by early-stage adoption, primarily within specialty neurology practices.
- Insurance coverage and prior authorization procedures influence patient access.
- The high price point restricts affordability, potentially leading to lower penetration rates initially.
Supply & Distribution
- Production capacity increased since approval, but supply constraints may influence pricing and availability.
- The company’s distribution leverage impacts regional availability and provider adoption.
Price Projections
Short-term (Next 12 Months)
- Retail prices are expected to remain stable around $8,000 per 10 mg vial.
- Reimbursement rates may pressure net prices downward by 10–15% due to payer negotiations.
- No significant drop in list price anticipated unless competitor biosimilars enter the market or new data drive price adjustments.
Mid-term (1-3 Years)
- Market expansion and increased approval indications might support a price increase of 5–8%, contingent on demand and formulation improvements.
- Biosimilar development remains unlikely within this period due to complex manufacturing processes for monoclonal antibodies.
Long-term (3-5 Years)
- Entry of biosimilar competitors could reduce prices by 30–50%, assuming regulatory approval and market uptake.
- Potential for negotiated discounts and value-based agreements could lower net prices.
Revenue Outlook and Pricing Factors
| Factor |
Impact |
Projection |
| Market size |
Limits revenue |
$300 million – $600 million in annual sales for gMG indication |
| Pricing |
High, with limited competition |
Stable list prices around $8,000 per vial |
| Competition |
Biosimilars may reduce prices |
30–50% price drop expected within 5 years |
Key Market Drivers
- Increasing recognition of gMG and expansion into pediatric indications.
- Improvements in patient access programs.
- Outcome data demonstrating superiority or comparable efficacy to existing treatment options.
- Regulatory advances facilitating broader indications or biosimilar approvals.
Risks
- Emergence of cost-effective biosimilars or oral alternatives.
- Payer restrictions limiting reimbursement.
- Slower-than-expected market penetration due to high treatment costs.
- Manufacturing delays impacting supply and pricing.
Summary
NDC 70677-1112, branded as Vyvgart, holds a high-price position within the rare disease therapeutic market for gMG. Its premium pricing sustains revenue under limited competition, though biosimilar threats and payer dynamics could influence future price trends. Expect prices to remain steady initially, with potential declines over a 3–5-year horizon due to biosimilar competition and market maturation.
Key Takeaways
- Vyvgart’s current list price is approximately $8,000 per 10 mg vial.
- Revenues are expected to be roughly $300–$600 million annually in the next few years.
- Biosimilar development may lead to price reductions of 30–50% within five years.
- Market expansion depends on increased diagnosis and coverage.
- Payer strategies and manufacturing capacity will influence future pricing trajectories.
FAQs
1. Will Vyvgart’s price decrease soon?
Likely not in the immediate term. Price reductions are anticipated in the 3–5-year window due to biosimilar competition and market saturation.
2. How does Vyvgart compare to other gMG treatments?
Vyvgart offers a targeted immunotherapy with a different mechanism of action compared to complement inhibitors like eculizumab, but at a higher cost.
3. What are the main barriers affecting sales growth?
High treatment costs, insurance coverage hurdles, and limited awareness among physicians constrain early adoption rates.
4. Are biosimilars in development?
Yes, multiple biosimilar candidates are in early regulatory or development stages, but none are approved yet.
5. How does the market size impact pricing?
A small patient population supports high per-vial prices but limits total revenue potential unless market share significantly increases.
References
[1] argenx SE. Vyvgart (efgartigimod alfa-fpes) Prescribing Information. 2022.
[2] U.S. Food and Drug Administration. Vyvgart (efgartigimod alfa-fpes) approval announcement. 2021.
[3] IQVIA. National Prescription Audit, 2022 Edition.
[4] EvaluatePharma. World Preview of Biosimilar Development, 2022.
